Clinical features and effectiveness of treatment of patients with pulmonary tuberculosis who have had COVID-19

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In May 2023, WHO officially declared the end of the COVID-19 pandemic. Assessing the consequences of the pandemic remains scientifically and practically relevant. Patients who have recovered from COVID-19 are at risk of developing or relapsing tuberculosis (TB). A comparative retrospective-prospective study was conducted on 88 patients with pulmonary TB, including 45 patients after COVID-19. In 68.9% of those examined, COVID-19 was mild. Tuberculomas and focal pulmonary TB predominated in patients. Tuberculomas and focal pulmonary TB predominated in patients. The most common patterns on CT scans were ground-glass and severe changes. Among laboratory parameters, increases in fibrinogen, D-dimer, and C-reactive protein were more often observed. COVID-19, which was mostly mild, did not have a significant impact on the effectiveness of treatment for TB patients. At the same time, such patients had a more frequent development of adverse reactions during anti-tuberculosis chemotherapy and a complicated course of pulmonary TB.

Full Text

Restricted Access

About the authors

A. V. Zakharov

Central Research Institute of Tuberculosis

Author for correspondence.
Email: Yrzahan@mail.ru

MD

Russian Federation, Moscow

N. L. Karpina

Central Research Institute of Tuberculosis

Email: Yrzahan@mail.ru

MD

Russian Federation, Moscow

N. A. Chernykh

Central Research Institute of Tuberculosis

Email: Yrzahan@mail.ru

Candidate of Medical Sciences

Russian Federation, Moscow

R. B. Amansakhedov

Central Research Institute of Tuberculosis

Email: Yrzahan@mail.ru

MD

Russian Federation, Moscow

I. E. Stepanyan

Central Research Institute of Tuberculosis

Email: Yrzahan@mail.ru

MD, Professor

Russian Federation, Moscow

V. V. Romanov

Central Research Institute of Tuberculosis

Email: Yrzahan@mail.ru

MD, Professor

Russian Federation, Moscow

A. E. Ergeshov

Central Research Institute of Tuberculosis; Russian University of Medicine, Ministry of Health of Russia

Email: Yrzahan@mail.ru

Corresponding Member of the Russian Academy of Sciences, MD, Professor

Russian Federation, Moscow; Moscow

References

  1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200708-covid-19-sitrep-170.pdf?sfvrsn=bca86036_2
  2. Ларина В.Н., Рыжих А.А., Бикбаева Л.И. Постковидный период: современный взгляд и клинические особенности. Архивъ внутренней медицины. 2021; 11(3): 186–95 [Larina V.N., Ryzhikh A.A., Bikbaeva L.I. Post-COVID 19 Period: Modern State and Clinical Features. The Russian Archives of Internal Medicine. 2021; 11 (3): 186–95 (in Russ.)]. doi: 10.20514/2226-6704-2021-11-3-186-195
  3. Malkova A.M., Kudryavtsev I.V., Starshinova A.A. et al. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021; 10 (11): 1408. doi: 10.3390/pathogens10111408
  4. Екатеринчева О.Л., Малкова А.М., Карев В.Е. и др. Особенности диагностики туберкулеза на фоне COVID-19. Журнал инфектологии. 2021; 13 (1): 117–23 [Ekaterincheva O.L., Malkova A.M., Karev V.E. et al. Features of tuberculosis diagnosis in the COVID-19. Journal Infectology. 2021; 13 (1): 117–23 (in Russ.)]. doi: 10.22625/2072-6732-2021-13-1-117-123
  5. Биличенко Т.Н. Постковидный синдром: факторы риска, патогенез, диагностика и лечение пациентов с поражением органов дыхания после COVID-19 (обзор исследований). РМЖ. Медицинское обозрение. 2022; 6 (7): 367–75 [Bilichenko T.N. Postcovid syndrome: risk factors, pathogenesis, diagnosis and treatment of patients with respiratory damage after COVID-19 (overview). Russian Medical Inquiry. 2022; 6 (7): 367–75 (in Russ.)]. doi: 10.32364/2587-6821-2022-6-7-367-375
  6. Эргешова Л.А., Борисова А.Ю., Карпина Н.Л. Клинические аспекты сочетания COVID-19 и хронических заболеваний органов дыхания – собственный опыт. Вестник ЦНИИТ. 2022; 4: 28–36 [Ergeshova L.A., Borisova A.Yu., Karpina N.L. Clinical aspects of a comorbidity of COVID-19 and chronic pulmonary disease – our experience. CTRI Bulletin. 2022; 4: 28–36 (in Russ.)]. doi: 10.57014/2587-6678-2022-4-28-36
  7. Бурячковская Л.И., Мелькумянц А.М., Ломакин Н.В. и др. Повреждение сосудистого эндотелия и эритроцитов у больных COVID-19. Consilium Medicum. 2021; 23 (6): 469–76 [Buryachkovskaya L.I., Melkumyants A.M., Lomakin N.V. et al. Injury of vascular endothelium and erythrocytes in COVID-19 patients. Consilium Medicum. 2021; 23 (6): 469–76 (in Russ.)]. doi: 10.26442/20751753.2021.6.200939
  8. Эргешов А.Э., Овсянкина Е.С., Губкина М.Ф., и др. Особенности диагностики и течения новой коронавирусной инфекции у детей и подростков с туберкулезом органов дыхания. Вестник ЦНИИТ. 2020; 4: 43–8 [Ergeshov A.E., Ovsyankina E.S., Gubkina M.F. et al. The peculiarities of diagnosis and course of the novel coronavirus infection in children and adolescents with pulmonary TB. CTRI Bulletin. 2020; 4: 43–9 (in Russ.)]. doi: 10.7868/S2587667820040056
  9. Красникова Е.В., Лепеха Л.Н., Багиров М.А. и др. Хирургическое лечение больных туберкулезом легких, перенесших COVID-19. Мат-лы конф. Оренбургская фтизиатрия и пульмонология. 2022; 1: 78–92 [Krasnikova E.V., Lepekha L.N., Bagirov M.A. et al. Khirurgicheskoe lechenie bol'nykh tuberkulezom legkikh, perenesshikh COVID-19. Mat-ly konf. Orenburgskaya ftiziatriya i pul'monologiya. 2022; 1: 78–92 (in Russ.)].
  10. Красникова Е.В., Лепеха Л.Н., Багиров М.А. и др. Опыт хирургического лечения больных туберкулезом легких, перенесших COVID-19. Мат-лы конф. Актуальные вопросы военной фтизиатрии. Пушкино, 2022; 13: 63–79 [Krasnikova E.V., Lepekha L.N., Bagirov M.A. et al. Opyt khirurgicheskogo lecheniya bol'nykh tuberkulezom legkikh, perenesshikh COVID-19. Mat-ly konf. Aktual'nye voprosy voennoi ftiziatrii. Pushkino, 2022; 13: 63–79 (in Russ.)].
  11. Мишина А.В., Мишин В.Ю., Эргешов А.Э. и др. Новая коронавирусная инфекция (COVID-19), сочетанная с туберкулезом, у больных на поздних стадиях ВИЧ-инфекции с иммунодефицитом. ВИЧ-инфекция и иммуносупрессии. 2021; 13 (1): 80–7 [Mishina A.V., Mishin V.Yu., Ergeshov A.E. et al. New coronoviral infection (COVID-19) combined with tuberculosis in patients at late stages of HIV infection with immunodeficiency. HIV Infection and Immunosuppressive Disorders. 2021; 13 (1): 80–7 (in Russ.)]. doi: 10.22328/2077-9828-2021-13-1-80-87
  12. Бородулина Е.А., Васнева Ж.П., Вдоушкина Е.С. и др. Особенности гематологических и гемостазиологических показателей при коронавирусной инфекции COVID-19 и внебольничной пневмонии. Acta Biomedica Scientifica. 2021; 6 (1): 40–7 [Borodulina E.A., Vasneva Zh.P. Vdoushkina E.S. et al. Features of hematological and hemostasiological parameters in coronavirus infection COVID-19 and community-acquired pneumonia. Acta Biomedica Scientifica. 2021; 6 (1): 40–7 (in Russ.)]. doi: 10.29413/ABS.2021-6.1.6
  13. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
  14. Kant S., Tyagi R. The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infect Dis. 2021; 8: 20499361211016972. doi: 10.1177/20499361211016973
  15. Wang Y., Xu J., Wang Y. et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: A rapid review and meta-analysis. Int J Clin Pract. 2021; 75: e14867. doi: 10.1111/ijcp.14867
  16. Васильева И.А., Тестов В.В., Стерликов С.А. Эпидемическая ситуация по туберкулезу в годы пандемии COVID-19 – 2020–2021 гг. Туберкулез и болезни легких. 2022; 100 (3): 6–12 [Vasilyeva I.A., Testov V.V., Sterlikov S.A. Tuberculosis Situation in the Years of the COVID-19 Pandemic – 2020-2021. Tuberculosis and Lung Diseases. 2022; 100 (3): 6–12 (in Russ.)]. doi: 10.21292/2075-1230-2022-100-3-6-12
  17. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 16. (18.08.2022) [Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiya 16. (18.08.2022) (in Russ.)]. URL: https://www.cr.minzdrav.gov.ru
  18. Туберкулез у взрослых. Федеральные клинические рекомендации 2022 г. [Tuberkulez u vzroslykh. Federal'nye klinicheskie rekomendatsii 2022 g. (in Russ.)]. URL: https://www.cr.minzdrav.gov.ru
  19. Ставицкая Н.В., Фелькер И.Г., Жукова Е.М. и др. Многофакторный анализ результатов применения бедаквилина в терапии МЛУ/ШЛУ-туберкулеза легких. Туберкулез и болезни легких. 2020; 98 (7): 56–62 [Stavitskaya N.V., Felker I.G., Zhukova E.M. et al. The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis. Tuberculosis and Lung Diseases. 2020; 98 (7): 56–62 (in Russ.)]. doi: 10.21292/2075-1230-2020-98-7-56-62
  20. Жукова Е.М., Вохминова Л.Г., Кудлай Д.А. Влияние современной химиотерапии туберкулеза с МЛУ/ШЛУ на изменение у больных интервала QT на ЭКГ. Туберкулез и болезни легких. 2019; 97 (11): 19–22 [Zhukova E.M., Vokhminova L.G., Kudlay D.A. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases. 2019; 97 (11): 19–22 (in Russ.)]. doi: 10.21292/2075-1 230-2019-97-11-19-22
  21. Lewandowski K., Rosołowski M., Kaniewska M. et al. Clostridioides difficile infection in coronavirus disease 2019 (COVID-19): an underestimated problem? Pol Arch Intern Med. 2021; 131: 121–7. DOI: 10.20 452/pamw.15715
  22. Spigaglia Р., Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Anaerobe. 2022; 74: 102518. doi: 10.1016/j.anaerobe.2022.102518
  23. Абдуллаев Р.Ю., Комиссарова О.Г. Невирусологические лабораторные маркеры COVID-19. Вестник ЦНИИТ. 2020; 3: 12–6 [Abdullaev R.Yu., Komissarova O.G. Non-virological laboratory markers of COVID-19. CTRI Bulletin. 2020; 3: 12–6 (in Russ.)]. doi: 10.7868/S2587667820030024
  24. Смирнова Т.Г., Андреевская С.Н., Ларионова Е.Е. и др. Опыт работы отдела микробиологии ФГБНУ «ЦНИИТ» в условиях пандемии COVID-19. Вестник ЦНИИТ. 2022; 2: 75–80 [Smirnova T.G., Andreevskaya S.N., Larionova E.E. et al. Experience of the microbiology department of the Central TB Research Institute in the context of COVID-19 pandemic. CTRI Bulletin. 2022; 2: 75–80 (in Russ.)]. doi: 10.7868/S2587667822020091
  25. Тиллоева З.Х. Динамика лекарственной устойчивости возбудителей туберкулеза во время пандемии новой коронавирусной инфекции в г. Душанбе: необходимость принятия срочных мер. Вестник Авиценны. 2022; 24 (3): 353–68 [Tilloeva Z.Kh. Dynamics of drug resistance in M. tuberculosis during the new coronavirus infection pandemic in Dushanbe: The need for urgent measures. Avicenna Bulletin. 2022; 24 (3): 353–68 (in Russ.)]. doi: 10.25005/2074-0581-2022-24-3-353-368

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. X-ray archive data

Download (67KB)
Indexing metadata
3. Fig. 2. Frequency of occurrence of different symptoms in the study groups

Download (129KB)
Indexing metadata
4. Fig. 3. Clinical forms of pulmonary tuberculosis in the study groups

Download (97KB)
Indexing metadata
5. Fig. 4. Comorbidities in the study groups

Download (129KB)
Indexing metadata
6. Fig. 5. CT signs of lung lesions in the study groups

Download (93KB)
Indexing metadata
7. Fig. 6. Drug resistance of Mycobacterium tuberculosis in the study groups

Download (99KB)
Indexing metadata
8. Fig. 7. Lung destruction cavity closure in the study groups

Download (39KB)
Indexing metadata
9. Fig. 8. Structure of adverse drug reactions

Download (86KB)
Indexing metadata

Copyright (c) 2024 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies